ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 124 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2015. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $2,000 | -60.0% | 400 | 0.0% | 0.00% | – |
| Q3 2021 | $5,000 | -37.5% | 400 | 0.0% | 0.00% | -100.0% |
| Q2 2021 | $8,000 | -27.3% | 400 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $11,000 | +10.0% | 400 | 0.0% | 0.00% | 0.0% |
| Q4 2020 | $10,000 | -33.3% | 400 | 0.0% | 0.00% | -50.0% |
| Q3 2020 | $15,000 | +15.4% | 400 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $13,000 | -45.8% | 400 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $24,000 | +118.2% | 400 | +33.3% | 0.00% | +100.0% |
| Q3 2019 | $11,000 | +22.2% | 300 | +50.0% | 0.00% | 0.0% |
| Q2 2019 | $9,000 | +200.0% | 200 | +227.9% | 0.00% | 0.0% |
| Q3 2017 | $3,000 | -99.9% | 61 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $3,000,000 | +50.0% | 61 | 0.0% | 0.00% | 0.0% |
| Q1 2017 | $2,000,000 | +100.0% | 61 | -33.7% | 0.00% | – |
| Q4 2016 | $1,000,000 | +99900.0% | 92 | 0.0% | 0.00% | – |
| Q3 2016 | $1,000 | 0.0% | 92 | +84.0% | 0.00% | – |
| Q3 2015 | $1,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |